Key facts
- This page summarizes Amit Sachdev's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 13 Feb 2024, 17:15.
Amit Sachdev - 09 Feb 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Reporting relationship
- EVP Chief Patient & Ext Af Off
- Issuer ticker
- VRTX
- Reported as of
- 09 Feb 2024
- Net transaction value
- -$2,208,794
- SEC form
- 4
- Accepted by SEC
- 13 Feb 2024, 17:15:30 UTC
- Prior SEC filing
- 08 Feb 2024
- Next SEC filing
- 21 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christiana Stevenson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amit Sachdev filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 13 Feb 2024.
Change
- Previous filing in this sequence was filed on 08 Feb 2024.
- Current net transaction value: -$2,208,794.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
transaction
Common Stock
Tax liability
- Transaction value
- $854,780
- Shares
- -2,022
- Change %
- -2.5%
- Price
- $422.74
- Shares after
- 77,586
- Date
- 09 Feb 2024
- Ownership
- Direct
VRTX
transaction
Common Stock
Sale
- Transaction value
- $1,354,013
- Shares
- -3,222
- Change %
- -4.2%
- Price
- $420.24
- Shares after
- 74,364
- Date
- 12 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 882
- Date
- 09 Feb 2024
- Ownership
- 401(k)
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,565
- Date
- 09 Feb 2024
- Ownership
- Held in Trust
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 1 footnote
Footnote F1
Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.